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Up to 14% of Malawian adults die during the intensive
phase of tuberculosis treatment. In a prospective cohort of
199 Malawian adults with microbiologically conﬁrmed
pulmonary tuberculosis, clinical and laboratory parameters
were compared between those who died or deteriorated
with those who had an uneventful recovery. Baseline tumor
necrosis factor alpha responses to stimulation with heat-
killed Mycobacterium tuberculosis and lipopolysaccharide
were reduced among the 22 patients with poor outcome
(P 5 .017). Low body mass index (P 5 .002) and elevated
respiratory rate (P 5 .01) at tuberculosis diagnosis in-
dependently predicted poor outcome. Validation of a clinical
score identifying high-risk individuals is warranted, together
with further investigation of immunological derangements.
In Malawi, up to 14% of tuberculosis (TB) patients die
during the 2-month intensive phase of therapy [1]. Although
cotrimoxazole prophylaxis and antiretroviral therapy
(ART) have been increasingly available since 2003 for the
two-thirds of TB patients who are coinfected with human
immunodeﬁciency virus (HIV), these have not signiﬁcantly
reduced early mortality [2].
Clinical deterioration [3] and poor outcome [4] have been
associated with elevated serum tumor necrosis factor alpha
(TNF-a), a pivotal proinﬂammatory cytokine. While sufﬁcient
production is necessary for an adequate host immune response,
excessive levels are associated with immunopathology [5]. Many
mycobacterial components provoke a proinﬂammatory re-
sponse [6]. Dysregulated proinﬂammatory responses may be
more pronounced in patients coinfected with TB and HIV; HIV
causes innate immune activation [7], whereas depletion of CD4
cells reduces interferon (IFN)-c production [8]. We hypothe-
sized that a proportion of patients deteriorate clinically or die
during the initial phase of TB treatment as a consequence of
a proinﬂammatory process.
METHODS
Patient Selection
Ambulatory and hospitalized adults with newly diagnosed
pulmonary tuberculosis (PTB) were recruited 2 mornings per
week at Queen Elizabeth Central Hospital, Blantyre, Malawi.
The resulting enrollment of 321 patients was a subset of the 3800
PTB cases registered between February 2007 and February 2009.
Exclusion criteria were: age ,16 years; known pregnancy;
previous TB; clinical evidence of extrapulmonary TB; and in
HIV-infected patients, already receiving ART.
Ethical approval for this study was granted by the College
of Medicine Research Ethics Committee, University of Malawi,
and the ethics committee of the Liverpool School of Tropical
Medicine.
Clinical Assessment
Under routine conditions in Blantyre, most patients commence
and complete treatment without further clinical assessment or
investigation. By contrast, study patients received additional
input, described below.
Prior to commencing treatment, a standardized assessment
involving detailed history, examination, and chest radiography
was undertaken. Full blood count (Coulter Hmx Hematology
Analyzer), CD4 count (Becton Dickinson FACScount),and HIV
testing (both Determine HIV 1/2 kit and Uni-Gold HIV-1/2 kit;
tie-breaker, SD Bioline HIV 1/2 kit) were performed. Three
additional sputum samples were collected for microbiological
conﬁrmation of the routine laboratory diagnosis. Patients were
deﬁned as smear positive if at least 1 acid-fast bacillus was
Received 20 October 2010; accepted 15 February 2011.
Potential conflicts of interest: none reported.
Correspondence: Catriona Waitt, BSc (Hons), MBChB (Hons), MRCP, DTM&H, The Wolfson
Centre for Personalised Medicine, Department of Pharmacology, University of Liverpool,
2nd Floor, Block A: Waterhouse Buildings, 1–5 Brownlow Street, Liverpool L69 3GL, UK
(cwaitt@liv.ac.uk).
The Journal of Infectious Diseases 2011;204:358–62
 The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases
Society of America. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
0022-1899 (print)/1537-6613 (online)/2011/2043-0007$14.00
DOI: 10.1093/infdis/jir265
358 d JID 2011:204 (1 August) d BRIEF REPORTdetected in at least 1 sputum sample by Ziehl–Neelsen staining [9]
and culture positive in accordance with standard methods [10].
Patients were reviewed on days 3, 7, 28, and 56 of TB treat-
ment. Additionally, patients were asked to present at any time if
they felt acutely unwell. This was considered an ‘‘acute episode’’;
full assessment was followed by investigation and management
as clinically indicated and feasible within our setting. An episode
was considered potentially life-threatening if hospitalization and
intensive medical input were required. The cause of each acute
episode or death was determined by 2 of the authors (CJW and
NPKB); discussion with a third clinician took place in the single
event of disagreement.
Patients who defaulted follow-up were traced in the com-
munity and the vital status of the patient was determined
when found. Consistent with national policy, eligible patients
commenced ART after the intensive phase of TB treatment.
Whole Blood Assay
The whole blood method described by Weir et al [11] was used.
Heparinized whole blood was diluted 1:5 with serum-free media
(RPMI 1640 medium, 2 mM L-glutamine, 100 IU/mL penicillin/
100 lg/mL streptomycin [all Sigma-Aldrich]). Quadruplicates
of 250 lL diluted blood were added to a 96-well tissue culture
plate (Fisher Scientiﬁc) and stimulated with 5 3 10
6 cfu/mL
heat-killed Mycobacterium tuberculosis H37Rv (HK) (a gift from
DrR Hartkoorn, University ofLiverpool),.01lg/mLEscherichia
coli, strain 055.b5 lipopolysaccharide (LPS) (Sigma-Aldrich), or
5 lg/mL phytohemagglutinin (PHA) (Sigma-Aldrich L8902);
a negative control of unstimulated blood was included. After
24 hours (HK and LPS) or 6 days (HK and PHA) incubation
in 5% CO2 at 37C, supernatants from quadruplicate wells
were harvested and stored at –80C until further analysis.
Cytokine Measurement
TNF-a and IFN-c were analyzed from stored supernatants
after clinical categorization of acute episodes by enzyme-linked
immunosorbent assay using antibody pairs and recombinant
cytokine standards, according to the manufacturer’s protocols
(BD Pharmingen). The lower limit of detection was 50 pg/mL
in both assays. Response to each antigen was calculated by
subtracting the value obtained from unstimulated blood.
Statistical Analysis
It was considered that without intervention, patients with
life-threatening acute episodes would likely have died. These
patients weretherefore groupeda prioritogetherwiththose who
died as ‘‘poor outcome’’ for comparison with ‘‘good outcome’’
patients who had an uncomplicated clinical course.
Associations between potential risk factors and poor outcome
wereexploredusingunivariatelogisticregression.Variableswith
P , .10 were included in backward multiple logistic regression,
being retained in the model at a signiﬁcance level of .05. Like-
lihood ratio tests were used to test signiﬁcance.
Mann–Whitney U tests were used to compare median
cytokine levels (GraphPad Prism version 5.00 for Windows,
GraphPad Software)
RESULTS
Description of Clinical Cohort
Of 321 patients enrolled, 221 (69%) had microbiologically
proven TB.Twopatients were withdrawn due toineligibility,and
17 elected to withdraw. Ten percent of patients defaulted; in all
but 3 patients, it was veriﬁed that the patient survived the
study period, either by locating the patient or by consulting the
‘‘cured’’ or ‘‘treatment completed’’ outcome category from
the TB registry. These were analyzed as protocol deviations.
Primary analysis was performed on the 199 patients with proven
TBwhoremainedinthestudy.Sixty-onepercentweremale,72%
were sputum smear positive, and 60% were HIV positive with
a median CD4 count of 150 (IQR, 68–346) cells/mm
3.F i f t e e n
(7.5%) were hospitalized at the time of TB diagnosis.
Description of Deaths and Acute Episodes
Twelve patients (6%) died during the study period after a me-
dian of 12 days; 8 during a hospital admission and 4 at
home. Eighty-threepercent wereHIV positive.Twopatientshad
self-presented with bacterial pneumonia (diagnosis based on
symptoms, clinical signs, and newlobar inﬁltrate on chest x-ray)
and failed to respond to aggressive ﬂuid and antibiotic therapy.
Two patients developed a septic shock–like presentation, 1 of
whom had Salmonella typhimurium isolated from the blood.
Six patients (50% of deaths) were thought to have died of
tuberculosis itself, and death was attributed to TB or another
HIV-related pathogen in the ﬁnal 2.
Sixteen patients (8%) presented with an acute episode after
a median of 18 days. Twelve of these were considered to be
potentially life threatening, requiring hospitalization. Sixty per-
cent of patients were HIV positive. In 50% of HIV-negative and
63% of HIV-positive patients, the cause of self-presentation with
a life-threatening acute episode was a presumed superadded in-
fection. Following intervention, 10 (83%) recovered clinically; 2
HIV-positive patients with superadded bacterial pneumonia died
(described above as deaths). Two patients with minor skin rashes,
1 with peripheral neuropathy, and 1 with a transient confusional
state that resolved spontaneously were not deemed severe.
The event rate in the patients without microbiologically
conﬁrmed disease (14 of 100) was not signiﬁcantly different
(X
2, 1.13; P 5 .29).
Baseline Clinical Factors Predicting Life-Threatening Acute
Episode or Death
Reduced systolic blood pressure, O2 saturation, bodymassindex
(BMI), hemoglobin, platelet count, CD4 count, and increased
BRIEF REPORT d JID 2011:204 (1 August) d 359respiratory rate and pulse were each signiﬁcantly associated with
poor outcome on univariate analysis(Table 1). Notably, there was
no signiﬁcant association with HIV status, duration of symptoms,
or whether the patient was an inpatient at the time of TB
diagnosis.
A backward stepwise approach for 175 patients with data on
all included variables identiﬁed low BMI (odds ratio [OR], 1.44;
95% conﬁdence interval [CI], 1.11–1.86; P 5 .002) and elevated
respiratory rate (OR, 1.81; 95% CI, 1.14–2.87; P 5 .01 per
5 breaths/min) as independent risk factors. Low BMI was
signiﬁcantly associated withpoor outcome in both HIV-positive
and HIV-negative patients.
Cytokine Production Using Whole Blood Assay
At the time of enrollment, in response to stimulation of whole
blood with both heat-killed H37Rv and LPS, there was signiﬁ-
cantly lower TNF-a production in patients with poor outcome
(median, 47 pg/mL [IQR, 0–346] in response to H37Rv and
142 pg/mL [IQR, 11–683] in response to LPS) compared with
good outcome (median, 290 pg/mL [IQR, 29–1116] in response
to H37Rv [P 5 .041] and 522 pg/mL [IQR, 58–1619] in
response to LPS [P 5 .017]) (Figure 1a). As a predictor of poor
outcome, ORs for deterioration were 1.72 (95% CI, .78–3.79;
P 5 .09) and 1.87 (95% CI, .94–3.73; P 5 .02) for each decre-
ment of 1000 pg/mL TNF-a produced in response to heat-killed
Table 1. Univariate Analysis of Risk Factors for Acute Episode or Death
Variable Median (range) or number in category Odds ratio 95% CI P value
Demographic Factors (OR is relative to nontabulated category)
Age .35 29 (15–70) 1.63 .64–4.13 .31
Female sex n 5 76 1.74 .65–4.67 .25
Clinical History and Examination
Categorical Variables (OR is relative to nontabulated category)
HIV positive (known or index presentation) n 5 120 1.74 .65–4.68 .26
Reported weight loss n 5 171 3.78 .49–29.3 .12
Shortness of breath n 5 146 1.69 .54–5.24 .34
Ever smoked n 5 50 .91 .31–2.65 .86
Inpatient at enrollment n 5 15 3.00 .75–12.00 .15
Bilateral chest signs n 5 30 1.97 .66–5.91 .24
Continuous Variables (OR is for the increase or decrease stated)
Duration of cough (per week) 6 (1–56) .99 .94–1.04 .71
Performance status (0–4)
a 1 (0–4) 1.60 .98–2.61 .07
Reduced BMI (per 1 kg/m
2) 18.5 (12.3–35.3) 1.53 1.19–1.96 ,.001
d
Increased temperature (per 1C) 37.4 (34–40.2) .92 .64–1.34 .68
Reduced O2 saturations (per 5% decrease) 96 (60–100) 1.72 1.09–2.71 .01
d
Increased respiratory rate (per 5 breaths/min) 16 (2–48) 1.82 1.16–2.85 .01
d
Increased pulse (per 10 beats/min)
b 105 (20–160) 1.26 1.01–1.57 .04
d
Reduced systolic blood pressure (per 5 mm Hg) 100 (60–160) 1.28 1.00–1.64 .04
d
Disorientation (0–3: time, place, or person) 3 (0–3) 2.31 .89–6.01 .10
Baseline Investigations
Categorical Variables
CD4 ,200 (HIV-positive patients only)
c n 5 64 3.67 .98–13.70 .03
d
Sputum smear negative n 5 110 1.80 .68–4.80 .24
Chest x-ray changes atypical for TB n 5 58 1.01 .35–2.88 .99
Continuous Variables (presented for a unit increase or decrease unless otherwise stated)
Reduced hemoglobin (g/dL) 9.9 (4.1–16.5) 1.38 1.09–1.75 .01
d
Total white cell count (10
9/L) 6.8 (1.3–21.7) .85 .69–1.04 .08
Monocyte count (10
9/L) 0.6 (01–5.1) .83 .30–2.30 .70
Reduced platelet count (per 10 3 10
9/L) 358 (18–928) 1.04 1.01–1.08 .01
d
Number of zones involved on chest x-ray 1 (0–6) 1.33 .93–1.90 .10
NOTE. BMI, body mass index; CI, conﬁdence interval; HIV, human immunodeﬁciency virus; OR, odds ratio; TB, tuberculosis.
a de Valliere S, Barker RD. Poor performance status is associated with early death in patients with pulmonary tuberculosis. Trans R Soc Trop Med Hyg
2006;100:681–6.
b Not signiﬁcant if patients lost to follow-up were considered to have suffered an adverse event.
c Not included in multiple logistic regression as only relevant for HIV-positive patients.
d Included in initial multivariate model.
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statistically signiﬁcant for multivariate analysis (P . .1). There
was no signiﬁcant difference in TNF-a from unstimulated blood
(data not shown). The trend was apparent in both HIV-positive
and HIV-negative individuals (data not shown); in the HIV-
positive subset, TNF-a production and CD4 count (data not
shown) were not correlated. Intracellular cytokine staining
showedthe monocytetobethemajorsourceofTNF-a (datanot
shown); monocyte count did not differ between the groups.
TNF-a production and BMI were not associated either at
baseline or following recovery.
Analysis of IFN-c production in response to stimulation
with both heat-killed H37Rv and PHA revealed no signiﬁcant
differences between outcome groups (Figure 1b).
DISCUSSION
This prospective cohort study investigated the causes, timing,
and risk factors for clinical deterioration and death during the
intensive phase of TB treatment in Malawi.
Independent predictors for poor outcome were low BMI and
elevated respiratory rate. Detailed clinical evaluation by experi-
enced clinicians yielded no additional beneﬁt in determining
risk. Simple clinical scoring systems enable triage and prioriti-
zation of medical admissions [12] but have not been studied in
relation to TB. Validation of a clinical score to predict risk in TB
patients is necessary in a larger cohort.
Using clinical criteria, half of the deaths in our study were
attributedtotuberculosis,andone-thirdmayhaveresultedfrom
intercurrent bacterial infection, although this was not univer-
sally proven microbiologically. Presumed bacterial infection was
the most common etiology for clinical deterioration not leading
to death, occurring with equal frequency in HIV-positive and
HIV-negative patients. All HIV-positive patients were receiving
cotrimoxazole prophylaxis in accordance with national policy
and Joint United Nations Programme on HIV/AIDS guidelines.
Knowledge of HIV status did not aid prediction of adverse
outcome during the intensive phase of TB treatment, directly
contrasting with ﬁndings from South Africa [13].
Signiﬁcantly lower TNF-a production occurred in response to
both TB and LPS in patients who subsequently died or suffered
signiﬁcant clinical deterioration, irrespective of HIV status, con-
trary to our hypothesis. A similar ﬁnding emerged from in-
vestigation of 41 Zambian TB patients, where 7 HIV-positive
patients died [14] but clinical predictors of poor outcome were
not identiﬁed.
Lower monocyte TNF-a production and the propensity for
bacterial infections among these patients suggest impaired in-
nate immune defenses. Monocyte dysfunction occurs in patients
with septic shock [15], predisposing to secondary bacterial in-
fection, which can be overwhelming. An analogous process, not
previously described in tuberculosis, may explain our ﬁndings;
work is ongoing to elucidate this process. Furthermore, cytokine
networks are increasingly recognized as pivotal to the outcome
of infectious diseases. Additional investigation of this Malawian
cohort will further compare the cytokine milieu in patients with
poor outcome to those with an uncomplicated clinical course.
There are some limitations to this study. No prior data
associated baseline TNF-a responses with clinical outcome,
making sample size calculation impossible. This is among the
largest longitudinal studies evaluating induced cytokine re-
sponses in TB patients. However, sample size was a limiting
factor in the development of a predictive model, and validation
in a larger cohort is needed. Limited diagnostic resources are
available in Malawi. Nonetheless, following appropriate treat-
ment, most patients with presumed superadded bacterial in-
fection recovered, suggesting that our diagnoses were correct.
Figure 1. Scattergraphs (and medians) of cytokine production in
response to stimulation of whole blood with heat-killed H37Rv,
lipopolysaccharide (LPS), and phytohemagglutinin (PHA) immediately
prior to the start of tuberculosis (TB) treatment. Patients who died or
suffered a significant acute episode are grouped together under ''poor
outcome'' whereas patients who had an uncomplicated clinical course
were considered to have a ''good outcome.'' A, Production of tumor
necrosis factor alpha (TNF-a) after 24 hours incubation. B, Production
of interferon (IFN)-c after 6 d incubation.
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Patients at risk of clinical deterioration after starting TB
treatment are identiﬁable using simple measurements in-
cluding BMI and respiratory rate. Further clinical studies
should seek to validate a simple clinical score for prediction of
risk in TB patients. Superadded bacterial infection is an im-
portant cause of deterioration, and is associated with de-
pressed monocyte responses to antigenic stimulation. Further
work should focus on the mechanisms underlying these im-
paired innate responses, as this may guide improved thera-
peutic and predictive strategies.
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